Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570297 · ClinicalTrials.gov registry record
Genetic Influences of Albuterol Response In Children With Bronchiolitis
A clinical trial, sponsored by Connecticut Children's Medical Center.
- Completed
- Registry status
- 54
- Enrollment target
NCT00570297: Completed study, sponsored by Connecticut Children's Medical Center.
NCT00570297 is a clinical trial that has completed, run by Connecticut Children's Medical Center. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570297 has completed, sponsored by Connecticut Children's Medical Center.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 hospitalizations per year in the U.S. Recently, genetic variations of the β2-adrenergic receptor (β2-AR) have been shown to influence response to β2-AR agonist therapy in children with asthma. We suspect that genetic variations of the β2-AR also affect response to β2-AR agonist therapy in children with bronchiolitis.
Primary Outcome
The primary end point is change in lung resistance following a single dose of inhaled b2-AR agonist therapy (albuterol).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-12 |
| Est. Completion | 2018-04 |
What the finished NCT00570297 record still lists
NCT00570297 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00570297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00570297 about?
NCT00570297 is a clinical study titled "Genetic Influences of Albuterol Response In Children With Bronchiolitis". Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 hospitalizations per year in the U.S. Recently, genetic variations of the β2-adrenergic receptor (β2-AR) have been shown to influence response to β2-AR agonist therapy in children ...
What is the current status of trial NCT00570297?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2007-12. Estimated completion is 2018-04.
Who is sponsoring clinical trial NCT00570297?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia